[go: up one dir, main page]

PE20120666A1 - Inhibidores de los virus flaviviridae - Google Patents

Inhibidores de los virus flaviviridae

Info

Publication number
PE20120666A1
PE20120666A1 PE2012000069A PE2012000069A PE20120666A1 PE 20120666 A1 PE20120666 A1 PE 20120666A1 PE 2012000069 A PE2012000069 A PE 2012000069A PE 2012000069 A PE2012000069 A PE 2012000069A PE 20120666 A1 PE20120666 A1 PE 20120666A1
Authority
PE
Peru
Prior art keywords
trans
carboxyl
methyl
thiophene
cyclohexanocarbonyl
Prior art date
Application number
PE2012000069A
Other languages
English (en)
Inventor
Eda Canales
Lee Chong
Michael O'neil Hanrahan Clarke
Edward Doerffler
Scott E Lazerwith
Willard Lew
Michael Mertzman
Philip A Morganelli
William J Watkins
Hong Ye
Qi Liu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20120666A1 publication Critical patent/PE20120666A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TIOFENO-2-CARBOXILICO DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C12), ALQUENILO(C2-C12), CICLOALQUILO(C3-C12), ENTRE OTROS; R2 ES ALQUINILO(C2-C12), CICLOALQUILO(C3-C12), ARILO(C6-C14), ENTRE OTROS; R3 ES ALQUILENO(C1-C12), ALQUENILENO(C2-C12), ARILENO(C6-C14), ENTRE OTROS; L ES -O-, -S-, -S(O)- O -S(O)2-; HET ES HETEROCICLILO DE 3 A 12 MIEMBROS O HETEROARILO DE 3 A 14 MIEMBROS OPCIONALMENTE SUSTITUIDOS CON Q4, EN DONDE Q4 ES HALOGENO, OXO, NO2, N(=O), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 5-(3,3-DIMETIL-BUT-1-INIL)-3-{(TRANS-4-METIL-CICLOHEXANOCARBONIL)-[TRANS-4-(PIRAZIN-2-ILOXI)-CICLOHEXIL]-AMINO}-TIOFENO-2-CARBOXILICO; ACIDO 5-(3,3-DIMETIL-BUT-1-INIL)-3-{(TRANS-4-METIL-CICLOHEXANOCARBONIL)-[TRANS-4-(6-METIL-PIRIDAZIN-3-ILOXI)-CICLOHEXIL]-AMINO}-TIOFENO-2-CARBOXILICO; ACIDO 5-(3,3-DIMETIL-BUT-1-INIL)-3-{(TRANS-4-METIL-CICLOHEXANOCARBONIL)-[TRANS-4-(PIRIDIN-3-ILOXI)-CICLOHEXIL]-AMINO}-TIOFENO-2-CARBOXILICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LOS VIRUS FLAVIVIRIDAE SIENDO UTILES EN EL TRATAMIENTO DE LA INFECCION POR EL VIRUS DE LA HEPATITIS C (HCV)
PE2012000069A 2009-07-21 2010-07-19 Inhibidores de los virus flaviviridae PE20120666A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22736709P 2009-07-21 2009-07-21
US24091109P 2009-09-09 2009-09-09
US35946610P 2010-06-29 2010-06-29

Publications (1)

Publication Number Publication Date
PE20120666A1 true PE20120666A1 (es) 2012-06-01

Family

ID=42711860

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000069A PE20120666A1 (es) 2009-07-21 2010-07-19 Inhibidores de los virus flaviviridae

Country Status (25)

Country Link
US (2) US8569302B2 (es)
EP (1) EP2475657B1 (es)
JP (2) JP5841531B2 (es)
KR (1) KR20120051022A (es)
CN (1) CN102471327A (es)
AP (1) AP3409A (es)
AR (1) AR077765A1 (es)
AU (1) AU2010276441B2 (es)
CA (1) CA2767088C (es)
CL (1) CL2012000147A1 (es)
CO (1) CO6491049A2 (es)
CR (1) CR20120081A (es)
DK (1) DK2475657T3 (es)
EA (1) EA020816B1 (es)
EC (1) ECSP12011684A (es)
ES (1) ES2427342T3 (es)
IL (1) IL217243A (es)
MX (1) MX2012000959A (es)
NZ (1) NZ597528A (es)
PE (1) PE20120666A1 (es)
SG (1) SG177709A1 (es)
TW (1) TW201116525A (es)
UY (1) UY32793A (es)
WO (1) WO2011011303A1 (es)
ZA (1) ZA201200940B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011011303A1 (en) * 2009-07-21 2011-01-27 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
NZ598208A (en) 2009-09-09 2014-02-28 Gilead Sciences Inc Inhibitors of flaviviridae viruses
HRP20130862T1 (hr) 2009-09-21 2013-10-25 Gilead Sciences, Inc. Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida
US8524764B2 (en) 2010-01-15 2013-09-03 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
CA2785567C (en) * 2010-01-15 2018-03-27 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
WO2012006055A2 (en) * 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
EA201300160A1 (ru) * 2010-07-22 2013-06-28 Новартис Аг 2,3,5-тризамещенные тиофены и их применение
SI2595980T1 (sl) 2010-07-22 2014-11-28 Gilead Sciences, Inc. Postopki in sestavki za zdravljenje paramyxoviridae virusnih infekcij
EP2734515B1 (en) * 2011-07-13 2015-11-04 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses
PL2864291T3 (pl) 2012-06-26 2017-07-31 Bayer Pharma Aktiengesellschaft N-[4-(chinolin-4-yloksy)cykloheksylo(metylo)](hetero)arylokarboksyamidy jako antagoniści receptora androgenowego, ich wytwarzanie i zastosowanie jako produktów medycznych
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
CN102964295B (zh) * 2012-12-17 2014-08-20 寿光富康制药有限公司 一种2-取代-4-（哌啶基甲基）吡啶的制备方法
EP2762124A1 (en) * 2013-01-31 2014-08-06 IP Gesellschaft für Management mbH Packaging comprising administration units of polymorphs, amorphous forms or solvates
US9492438B2 (en) * 2014-07-25 2016-11-15 Bette Pollard Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
ES2892123T3 (es) 2014-12-26 2022-02-02 Univ Emory Derivados antivíricos de N4-hidroxicitidina
LT3785717T (lt) 2015-09-16 2022-04-11 Gilead Sciences, Inc. Coronaviridae infekcijų gydymo būdai
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN116655730A (zh) 2016-06-01 2023-08-29 雅斯娜 用于治疗多种疾病的n-己酸-l-酪氨酸-l-异亮氨酸-(6)-氨基己酰胺的衍生物
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
CA3178212A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
EP3651734B1 (en) 2017-07-11 2024-11-13 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
CA3169340A1 (en) 2020-03-12 2021-09-16 Pavel R. Badalov Methods of preparing 1'-cyano nucleosides
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
DK4204421T3 (da) 2020-08-27 2024-05-27 Gilead Sciences Inc Forbindelser og fremgangsmåder til behandling af virale infektioner
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
TWI867455B (zh) 2022-03-02 2024-12-21 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861421A (en) 1995-12-21 1999-01-19 Smithkline Beecham Corporation 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds
US20020002199A1 (en) 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
US20050119332A1 (en) 1998-03-12 2005-06-02 Lone Jeppesen Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
JP2005500287A (ja) 2001-06-11 2005-01-06 シャイアー バイオケム インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の処置または予防のための化合物および方法
WO2002100851A2 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
ATE466856T1 (de) 2002-12-10 2010-05-15 Virochem Pharma Inc Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
US7402608B2 (en) 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
DE10359791A1 (de) 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
WO2005081954A2 (en) 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
CA2561977A1 (en) 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
DE102005028077A1 (de) 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
SG161315A1 (en) * 2005-05-13 2010-05-27 Virochem Pharma Inc Compounds and methods for the treatment or prevention of flavivirus infections
CA2636879A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
BRPI0718915A2 (pt) 2006-11-15 2013-12-03 Virochem Pharma Inc Análogos de tiofeno para o tratamento ou prevenção de infecções por flavivírus
WO2008059042A1 (en) 2006-11-17 2008-05-22 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti viral agents
EA201190007A1 (ru) 2008-12-03 2012-06-29 Пресидио Фармасьютикалс, Инк. Ингибиторы ns5a вгс
WO2011011303A1 (en) * 2009-07-21 2011-01-27 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
NZ598208A (en) 2009-09-09 2014-02-28 Gilead Sciences Inc Inhibitors of flaviviridae viruses
CA2781614A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
US8524764B2 (en) 2010-01-15 2013-09-03 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
CA2785567C (en) 2010-01-15 2018-03-27 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
WO2012006055A2 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections

Also Published As

Publication number Publication date
CL2012000147A1 (es) 2012-09-07
IL217243A0 (en) 2012-02-29
JP2015205940A (ja) 2015-11-19
CA2767088C (en) 2018-07-10
JP5841531B2 (ja) 2016-01-13
TW201116525A (en) 2011-05-16
AR077765A1 (es) 2011-09-21
AP2012006085A0 (en) 2012-02-29
US20140030223A1 (en) 2014-01-30
AU2010276441B2 (en) 2015-07-02
EP2475657A1 (en) 2012-07-18
CR20120081A (es) 2012-07-04
KR20120051022A (ko) 2012-05-21
WO2011011303A1 (en) 2011-01-27
EA201290053A1 (ru) 2012-07-30
ECSP12011684A (es) 2012-04-30
EP2475657B1 (en) 2013-06-12
US20110020278A1 (en) 2011-01-27
EA020816B1 (ru) 2015-01-30
CO6491049A2 (es) 2012-07-31
JP2012533630A (ja) 2012-12-27
HK1166788A1 (en) 2012-11-09
CA2767088A1 (en) 2011-01-27
NZ597528A (en) 2014-08-29
ZA201200940B (en) 2014-07-30
MX2012000959A (es) 2012-03-06
CN102471327A (zh) 2012-05-23
UY32793A (es) 2011-01-31
AP3409A (en) 2015-08-31
SG177709A1 (en) 2012-02-28
AU2010276441A1 (en) 2012-02-02
ES2427342T3 (es) 2013-10-30
IL217243A (en) 2014-07-31
DK2475657T3 (da) 2013-09-23
US8569302B2 (en) 2013-10-29

Similar Documents

Publication Publication Date Title
PE20120666A1 (es) Inhibidores de los virus flaviviridae
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
PE20140109A1 (es) Inhibidores del virus de la hepatitis c
PE20130281A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
PE20091381A1 (es) Inhibidores del virus de la hepatitis c
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
PE20080992A1 (es) Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c
CY1113752T1 (el) Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
PE20091000A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
NO20084645L (no) Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer
PE20071326A1 (es) Inhibidores de la polimerasa viral
AR078976A1 (es) Inhibidores heterociclicos de la proteina ns5a codificada por el virus de la hepatitis c(vhc), composiciones farmaceuticas que los comprenden y uso de los mismos para tratar infecciones por vhc
AR075510A1 (es) Inhibidores del virus de la hepatitis c
PE20120257A1 (es) Analogos carba-nucleosidicos para tratamiento antiviral
EA201100482A1 (ru) Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
EA201171152A1 (ru) Ингибиторы вируса гепатита c
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
PE20120995A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
DE602007009646D1 (de) Hcv-ns5b-inhibitoren
AR076274A1 (es) Inhibidores del virus de la hepatitis c
EA200701849A1 (ru) Пролекарственные соединения трициклических нуклеозидов, фармацевтическая композиция на их основе и способ лечения и/или ингибирования вирусной инфекции у млекопитающего
PE20091458A1 (es) Compuestos heterociclicos antiviricos

Legal Events

Date Code Title Description
FC Refusal